Clinical Trials

Paclitaxel Extends Life of Ovarian Cancer Patients

Published in Cancer Weekly, June 12th, 1995

Women with advanced ovarian cancer extended their average survival time by 13 months, or 50 percent, when they received the drug paclitaxel in combination with cisplatin.

The therapy allowed women a median survival time of 37.5 months, compared to 24.4 months with the standard chemotherapy of cisplatin and cyclophosphamide. The findings come from clinical trials of nearly 400 women conducted by William McGuire, M.D., professor of medicine, Winship Cancer Center of Emory University.

This is the first time in more than 15 years, since cisplatin was developed and incorporated into the initial therapy of ovarian cancer, that these patients have shown a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-06-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry